Petros Pharmaceuticals, Inc. Repayments of Debt
Petros Pharmaceuticals, Inc. (PTPI) reported Repayments of Debt of $6.65 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2022-11-15
- Petros Pharmaceuticals, Inc. repayments of debt for the quarter ending 2021-12-31 was $1.74M, a 12.89% increase year-over-year.
- Petros Pharmaceuticals, Inc. repayments of debt for the quarter ending 2021-09-30 was $1.68M, a 12.66% increase year-over-year.
- Petros Pharmaceuticals, Inc. repayments of debt for the quarter ending 2021-06-30 was $1.64M, a 7.62% increase year-over-year.
- Petros Pharmaceuticals, Inc. repayments of debt for the quarter ending 2021-03-31 was $1.59M, a 1.99% decline year-over-year.
- Petros Pharmaceuticals, Inc. repayments of debt for fiscal 2021 was $6.65M, a 7.63% increase from fiscal 2020.
- Petros Pharmaceuticals, Inc. repayments of debt for fiscal 2020 was $6.18M.
| Period end | Repayments of Debt | Repayments of Debt 1 month | Repayments of Debt 3 month | Repayments of Debt 6 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|---|---|---|
| 2021-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.43M derived: sum of 2 quarters · filed 2022-03-31 | $5.06M derived: sum of 3 quarters · filed 2022-03-31 | $6.65M 10-K · filed 2022-03-31 | ||
| 2021-11-30 | $1.20M 10-Q · filed 2021-11-15 | |||||
| 2021-11-03 | $1.18M 10-Q/A · filed 2022-11-15 | |||||
| 2021-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.32M derived: sum of 2 quarters · filed 2021-11-15 | $4.91M 10-Q · filed 2021-11-15 | $6.45M derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2021-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $3.23M 10-Q · filed 2021-08-16 | $4.77M derived: sum of 3 quarters · filed 2022-03-31 | $6.27M derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2021-03-31 | $1.59M 10-Q · filed 2021-05-14 | $3.13M derived: sum of 2 quarters · filed 2022-03-31 | $4.63M derived: sum of 3 quarters · filed 2022-03-31 | $6.15M derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2020-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $3.04M derived: sum of 2 quarters · filed 2022-03-31 | $4.56M derived: sum of 3 quarters · filed 2022-03-31 | $6.18M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.02M derived: sum of 2 quarters · filed 2021-11-15 | $4.64M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $3.14M 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | $1.62M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |